|
|
"Enhancement of Brain Tumor Immunotherapy by Fas-L RNAi"
|
5R33CA112148-04
|
$348,500
|
$348,500
|
Olivi, Alessandro
|
JOHNS HOPKINS UNIVERSITY
|
|
|
A Novel Inhibitor of Stat3 for Prostate Cancer Therapy
|
5R01CA104035-05
|
$280,899
|
$280,899
|
JING, NAIJIE
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
A Novel Microfluidic Device for Selection and Optimization of Drug Delivery Vehic
|
1R43CA139841-01
|
$157,928
|
$39,482
|
PRABHAKARPANDIAN, BALABHASKAR
|
CFD RESEARCH CORPORATION
|
|
|
A Pilot Study of 5-FC and Genetically-Modified Neural Stem Cells to Treat Gliomas
|
1R21CA137639-01A1
|
$365,200
|
$91,300
|
PORTNOW, JANA
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
ADAM 17 and glioma-tumor progression and treatment
|
1R01CA129446-01A2
|
$300,875
|
$99,289
|
JIANG, FENG
|
HENRY FORD HEALTH SYSTEM
|
|
|
Adenovirus-host interactions and in vivo virus targeting
|
1R01CA141439-01A2
|
$548,316
|
$548,316
|
SHAYAKHMETOV, DMITRY
|
UNIVERSITY OF WASHINGTON
|
|
|
Adoptive Cell Transfer Immunotherapy of Cancer
|
ZIA BC 010984
|
$1,264,583
|
$505,833
|
Rosenberg, Steven
|
CCR (NCI)
|
|
|
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells
|
1R01CA138738-01
|
$393,420
|
$393,420
|
Brentjens, Renier
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
|
ALL Fusion Proteins: Associated with Multi-protein Complexes and Role in Transcri
|
5R01CA128609-04
|
$308,345
|
$308,345
|
CROCE, CARLO
|
OHIO STATE UNIVERSITY
|
|
|
An Anti-tumor Therapy Utilizing EP to Deliver IL-15 into B16.F10 Melanoma
|
5F31CA119950-02
|
$31,970
|
$31,970
|
MARRERO, BERNADETTE
|
UNIVERSITY OF SOUTH FLORIDA
|
|
|
Antiangiogenic Gene Therapy of Ovarian and Breast Cancers
|
5R01CA114340-03
|
$253,350
|
$253,350
|
RAMAKRISHNAN, SUNDARAM
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
|
Antibody Neutralization of Therapeutic Viruses
|
5R01CA129966-02
|
$500,247
|
$125,062
|
RUSSELL, STEPHEN
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
|
Antibody-mediated Gene Therapy for the Treatment of Cancer
|
1K01CA138559-01A1
|
$136,347
|
$68,174
|
Daniels, Tracy
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
AP-1 Complexes and Target Gene Regulation
|
5R01CA114381-04
|
$255,881
|
$63,970
|
TAPAROWSKY, ELIZABETH
|
PURDUE UNIVERSITY WEST LAFAYETTE
|
|
|
Aptamer-siRNA Chimeras Targeting HER2-Positive Breast Cancers
|
1R01CA138503-01A1
|
$311,250
|
$311,250
|
Giangrande, Paloma
|
UNIVERSITY OF IOWA
|
|
|
Armed Replicating Ad for Breast Cancer Bone Metastasis
|
5R01CA108585-04
|
$225,695
|
$112,848
|
Douglas, Joanne
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
|
Astrocytic Cancers: How, When, Where?
|
3U01CA084314-10S1
|
$75,305
|
$15,061
|
VAN DYKE, TERRY
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
|
|
Biodegradable Polymers For DNA Vaccine Delivery
|
5R01CA129189-02
|
$306,550
|
$153,275
|
WANG, CHUN
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
|
Biology & Transplantation of the Human Stem Cell
|
5P01CA065493-15
|
$2,135,909
|
$1,601,932
|
MCGLAVE, PHILIP
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
|
Bone Marrow Transplantation in Human Disease
|
5P01CA015396-34
|
$3,012,562
|
$301,256
|
JONES, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
|
|
Boosting anti-tumor immune responses by modulating genes with nanoparticles
|
1R21CA132026-01A1
|
$179,782
|
$179,782
|
Conejo-Garcia, Jose
|
DARTMOUTH COLLEGE
|
|
|
Cancer Center Training - Experimental Therapy Models
|
2T32CA009363-26A2
|
$353,821
|
$53,073
|
LAND, HARTMUT
|
UNIVERSITY OF ROCHESTER
|
|
|
Cancer dual-targeting of an infectivity-enhance CRAd
|
3R42CA114921-02A2S1
|
$40,000
|
$40,000
|
MATHIS, J
|
VECTORLOGICS, INC.
|
|
|
Cancer dual-targeting of an infectivity-enhance CRAd
|
5R42CA114921-03
|
$412,501
|
$412,501
|
MATHIS, J
|
VECTORLOGICS, INC.
|
|
|
Cancer Education Program
|
5R25CA020449-32
|
$271,749
|
$54,350
|
Fahey, Thomas
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
|
Carbocyclic Nucleoside Isosteres as Potential Antitumor and Antiviral Agents
|
ZIA BC 006174
|
$126,285
|
$12,628
|
Marquez, Victor
|
CCR (NCI)
|
|
|
Career Development in Pediatric and Medical Oncology
|
2K12CA076930-11
|
$595,080
|
$119,016
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
CD8+ T cells and Immunological Tumor Regression
|
5P01CA097296-07
|
$1,493,912
|
$224,087
|
Schreiber, Hans
|
UNIVERSITY OF CHICAGO
|
|
|
Cell Prep Core
|
ZIC BC 010905
|
$1,143,255
|
$571,627
|
Wunderlich, John
|
CCR (NCI)
|
|
|
Cell Production Facility Core
|
ZIC BC 011020
|
$1,143,255
|
$571,627
|
Dudley, Mark
|
CCR (NCI)
|
|
|
Cell Therapy of Refractory Leukemia
|
5R01CA113482-04
|
$289,553
|
$95,552
|
CAMPANA, DARIO
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
|
Cellular co-factors in stable retroviral transduction
|
5R01CA125272-03
|
$235,600
|
$235,600
|
DANIEL, RENE
|
THOMAS JEFFERSON UNIVERSITY
|
|
|
Cellular Transduction with Replication-Competent Retrovirus Vectors
|
5R01CA121258-03
|
$481,936
|
$481,936
|
KASAHARA, NORIYUKI
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
Center for Molecular Imaging Research at MGH/HMS
|
5P50CA086355-10
|
$1,942,000
|
$485,500
|
WEISSLEDER, RALPH
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
|
Characteristics of Multidrug Resistance in Human Tumors
|
5R01CA040570-22
|
$261,339
|
$65,335
|
BECK, WILLIAM
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
|
|
Chitosan-plasmid DNA nanoplexes and adenoviruses as prostate cancer vaccines
|
5R21CA133456-02
|
$168,750
|
$84,375
|
SALEM, ALIASGER
|
UNIVERSITY OF IOWA
|
|
|
Chronic Lymphocytic Leukemia Research Consortium
|
3P01CA081534-10S1
|
$113,755
|
$22,751
|
KIPPS, THOMAS
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
|
Chronic Lymphocytic Leukemia Research Consortium
|
5P01CA081534-10
|
$3,970,539
|
$794,108
|
KIPPS, THOMAS
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
|
City of Hope Lymphoma SPORE
|
3P50CA107399-05S1
|
$1,079,832
|
$269,958
|
forman, stephen
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
4R44CA124032-02
|
$1,473,388
|
$1,473,388
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
|
Clinical and Laboratory Studies of Malignant Lymphomas
|
5P01CA034233-25
|
$1,717,701
|
$343,540
|
LEVY, RONALD
|
STANFORD UNIVERSITY
|
|
|
Clinical study of AdV-tk radiogene therapy for malignant glioma
|
5R44CA107745-05
|
$510,001
|
$510,001
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
|
Combination Gene Therapy and Th1/Th2 Therapy
|
ZIA BC 011219
|
$240,008
|
$120,004
|
Fowler, Daniel
|
CCR (NCI)
|
|
|
Combination gene therapy for metastatic colon cancer
|
5R01CA070337-13
|
$287,106
|
$287,106
|
CHEN, SHU-HSIA
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
|
|
Conditionally Replicative Adenoviral Vectors for Malignant Glioma
|
5R01CA122930-02
|
$312,556
|
$312,556
|
LESNIAK, MACIEJ
|
UNIVERSITY OF CHICAGO
|
|
|
Converting an Oncogene to an Apoptotic Factor by Manipulating Signal Sequences
|
5R01CA129528-02
|
$283,656
|
$283,656
|
LIM, CAROL
|
UNIVERSITY OF UTAH
|
|
|
Coordinating Cell Killing by Communication: Biological Control and Cancer Therapy
|
5R01CA118486-04
|
$208,402
|
$208,402
|
YOU, LINGCHONG
|
DUKE UNIVERSITY
|
|
|
Cytokine Gene Therapy of Cancer - Preclinical Studies
|
5P01CA100327-05
|
$858,309
|
$858,309
|
Storkus, Walter
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
|
Cytokine Regulation of Normal and Neoplastic Hematopoietic Cell Growth
|
ZIA BC 009264
|
$576,162
|
$11,523
|
Ruscetti, Francis
|
CCR (NCI)
|
|
|
Developing Multi-Genic Anti-Breast Cancer Therapies
|
5R01CA109174-04
|
$283,865
|
$283,865
|
DEBS, ROBERT
|
CALIFORNIA PACIFIC MED CTR RES INSTITUTE
|
|
Total relevant funding to Gene Therapy for this search: $68,363,970
|
